CarThera has demonstrated the feasibility of its SonoCloud approach in previous glioblastoma studies and actively supports institutional research. The SoniMel study, sponsored by Greater Paris University Hospitals and funded by the French National Cancer Institute, aims to demonstrate the safety of the procedure for patients with brain metastases from melanoma and to determine the optimal dose for further developments in this indication. The study is expected to finish in mid-2021.
“Enormous progress has been made in treating melanoma with new therapies, but despite progress in the treatment of brain metastases, therapeutic challenges are still high. In this respect, the SoniMel protocol is extremely important because of its technological innovation in opening the blood-brain barrier,” said Professor Céleste Lebbé, principal investigator at Saint Louis Hospital, Paris.
In this trial, the checkpoint inhibitors (anti-PD1 alone or in combination with anti-CTLA4) are administered in metastatic melanoma patients before SonoCloud-mediated blood-brain barrier opening (BBB). BBB opening can help boost the brain’s immunity and increase brain penetration of newly approved systemically delivered immunotherapies, such as checkpoint inhibitors. This could translate into controlling brain disease with the same magnitude as peripheral diseases, improving clinical outcomes for many patients worldwide.
“This study is of great interest for CarThera, as it targets a high unmet medical need, that of secondary tumors,” said Frederic Sottilini, CEO at CarThera. “The incidence of brain metastases is high in patients with melanoma, lung or breast cancer. The functional and vital prognosis is severe. Opening the blood-brain barrier with the SonoCloud system in patients treated with immunotherapies for brain metastases is an interesting avenue to explore in improving the brain’s immunological response.”
Brain tumors are diagnosed in 10 to 40 percent of metastatic melanoma patients. Across all cancers, an estimated 100,000 to 170,000 new cases of brain metastasis are diagnosed annually. With the brain metastases indication, CarThera anticipates it will considerably expand the market potential of its SonoCloud innovation.
“This is the fourth clinical trial to evaluate SonoCloud’s technology for treatment of brain diseases,” said Carole Desseaux, chief clinical officer at CarThera. “So far, a total of 45 patients have been treated with the SonoCloud implantable ultrasound device, representing about 180 sonication sessions.”
SonoCloud is a medical device developed by CarThera. It emits ultrasound to temporarily increase the permeability of the blood vessels in the brain. Invented by Pr. Alexandre Carpentier, SonoCloud is an implant inserted into the skull and activated prior to chemotherapy. Several minutes of low-intensity ultrasound opens the blood-brain barrier for six hours and increases the concentration of therapeutic molecules in the brain. The SonoCloud technology is appropriate for the treatment of brain diseases in general. Oncology indications are the company’s primary target but investigations are ongoing in other conditions, including neurodegenerative diseases and Alzheimer’s disease in particular.